Transcarent
PrivateLast Round
M&A
Apr 8, 2025
Est. Valuation
$2.2B
Total Funding Raised
$424M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Transcarent is a healthtech company that provides a consumer-directed health and care platform for employees of self-insured employers and their families.
Sector
Healthcare & Life Sciences
Verticals
Patient Engagement, Telemedicine, NLP & Conversational AI, Healthcare Analytics, Mental Health
Business Model
B2B2C
Customer Profile
Revenue Share, Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Transcarent Comparables
Compare Transcarent with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Included Health | 86% | |
| Garner Health | 85% | |
| Quantum Health | 85% |
Transcarent Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Apr 8, 2025 | ||||
| Series D | May 2, 2024 | ||||
| Series C | Jan 11, 2022 | ||||
| Series B | Jun 10, 2021 | ||||
| Series A | Oct 22, 2020 |
Key People
Founding team and executive leadership
Transcarent Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series D, Series C |
| GreatPoint Ventures | Series C, Series B |
| Geodesic Capital | Series D |
| Threshold Ventures | Series C, Series B, Series D |
| Ally Bridge Group | Series C, Series D |
| M13 | Series C, Series B |
| GreatPoint Ventures | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 21, 2026
Open roles increased to 1,706, 203% of headcount.
- Sep 17, 2026
Grew 18% QoQ, from 810 to 956 employees.
Recent news
Latest coverage and updates
- partners_withOct 13, 2026
On Oct 13th '26, Transcarent and OrthoForum Value Network partner to expand access to orthopedic surgery through more than 160 independent practices across 47 states, coordinated referrals and scheduling, and bundled pricing.
- launchesAug 27, 2026
Transcarent launches a bundled payment model for BiTE and CAR T cancer therapies through high-quality community providers in California on Aug 25th '26., helping bring advanced care closer to patients while giving employers more predictable oncology costs.
- partners_withAug 25, 2026
As of Aug 25th '26, Transcarent is working with Vantrishealth to expand access to advanced cancer therapies through integrated navigation, quality, and value-based payment models in community oncology settings nationwide.
- hiresAug 6, 2026
Transcarent appoints Mike Morgan as Chief Commercial Officer in California on Aug 6th '26, with Morgan leading sales, partnerships, and go-to-market strategy across employers, health plans, and strategic partners.
Transcarent Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Transcarent's valuation, stock price, and market status.
Is Transcarent a public or private company?
Transcarent is a private company.
What is the current stock price of Transcarent?
Transcarent is a private company, so its shares have no public market price. Caplight tracks Transcarent's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Transcarent worth (valuation)?
Transcarent's valuation is estimated at $2.2B based on funding round data.
Can I buy Transcarent stock?
Transcarent shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Transcarent's last funding round?
Transcarent's most recent funding round was M&A on April 8, 2025.
Who are the main investors in Transcarent?
Key investors in Transcarent include Human Capital, 7wire Ventures, General Catalyst, 62 Ventures, Kinnevik.
Will Transcarent IPO soon?
No public IPO plans have been announced for Transcarent.
How can I track Transcarent secondary market activity?
Caplight tracks bids, offers, and trades in Transcarent's shares on secondary markets.